Hematologic markers predict nasopharyngeal cancer survival

September 22, 2015
Hematologic markers predict nasopharyngeal cancer survival

(HealthDay)—Pretreatment neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) may be predictors for survival in nasopharyngeal carcinoma, according to a study published online Sept. 11 in Head & Neck.

Wei Sun, M.D., from the Huazhong University of Science and Technology in Wuhan, China, and colleagues evaluated the prognostic significance of various hematologic parameters in 251 patients with .

The researchers found that NLR ≥2.7 (hazard ratio, 2.01; P = 0.005) and PLR ≥167.2 (hazard ratio, 2.12; P = 0.001) were significantly associated with shorter progression-free survival, while PLR ≥163.4 was correlated with poor overall survival (hazard ratio, 2.64; P = 0.011).

"Pretreatment NLR and PLR can be independent prognostic factors for patients with NPC," the authors write.

Explore further: Enoxaparin prevents VTEs in advanced pancreatic cancer

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Enoxaparin prevents VTEs in advanced pancreatic cancer

May 20, 2015
(HealthDay)—For patients with advanced pancreatic cancer (APC), enoxaparin is effective for prevention and treatment of venous thromboembolic events (VTEs), according to a study published online May 18 in the Journal of ...

Metformin linked to lower risk of head, neck cancer

September 9, 2015
(HealthDay)—Metformin is associated with a lower risk of developing head and neck cancer in patients with diabetes, according to a study published in the September issue of Head & Neck.

ERCC1 SNP can identify good prognosis in nasopharyngeal CA

August 27, 2015
(HealthDay)—Excision repair cross-complementing group 1 (ERCC1) genotype for the single nucleotide polymorphism (SNP) cytosine-to-thymine substitution at codon 118 (C118T) interacts with post-radiotherapy plasma Epstein-Barr ...

Antigen level signals response to chemo for pancreatic cancer

August 17, 2015
(HealthDay)—A drop in carbohydrate antigen (CA) 19-9 levels of more than 10 percent after two rounds of chemotherapy is associated with longer survival in patients with advanced pancreatic ductal adenocarcinoma (PDAC), ...

KRAS mutations predict shorter survival in lung cancer

July 26, 2012
(HealthDay) -- For patients with advanced lung adenocarcinomas, KRAS mutations predict shorter survival, according to a study published online July 18 in Cancer.

Treatments show promise in metastatic melanoma

November 18, 2014
(HealthDay)—In metastatic melanoma, nivolumab improves overall and progression-free survival versus dacarbazine, and dabrafenib plus trametinib improves survival versus vemurafenib monotherapy, according to two studies ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.